Adding inavolisib to palbociclib and fulvestrant more than doubled the median progression-free survival in the phase 3 INAVO120 trial. Adding inavolisib to palbociclib and fulvestrant improved PFS in patients with PIK3CA-mutant, HR+, HER2- advanced breast cancer.
Safe Paths to Motherhood for HR-Positive Breast Cancer Survivors medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.
A Majority of Subjects in Jaguar Health s Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II torontotelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from torontotelegraph.com Daily Mail and Mail on Sunday newspapers.
A clinical trial suggests younger post-menopausal women with early-stage HR-positive/HER2-negative breast cancer may safely omit radiation therapy if they continue endocrine therapy.